Cholate Clearance in Fontans
Development of a Reliable Means for Functional Assessment of Liver Performance After the Fontan Operation: Dual Cholate Clearance Assay
HepQuant is an assay to measure liver function in other forms of liver disease such as hepatitis C. It measures the ability of the liver to process an naturally occurring substance called cholate and has been shown to predict clinical outcomes in some patient populations.
The Fontan survivor is a patient who has undergone surgery or a series of surgeries that result in a functional single ventricle. The liver is particularly vulnerable to disease including congestion, fibrosis, and even cirrhosis. Currently liver function in the Fontan is not well-characterized and the HepQuant assay could help answer this question.
Studieoversigt
Detaljeret beskrivelse
A novel test called HepQuant® is an assay that has been used to measure liver function in other types of liver disease. In these populations, it is hoped that the assay may show more subtle or sub-clinical liver abnormalities that blood tests alone cannot detect. HepQuant® is a test that examines the ability of the liver to process a substance called cholate, which is a naturally occurring substance in the body. Cholate gets to the liver 2 ways: through the gut (by mouth) or through the blood (IV or intravenous). The test involves administering oral and IV cholate which is labeled. This label is NOT radioactive, but can act as an indicator/marker for evaluation purposes.
The purpose of this study is to develop a reliable means of measuring liver function in the Fontan survivor by examining cholate clearance. The investigators aim to 1) explore any association between level of cholate clearance and measurement of heart and liver function and 2) determine whether cholate clearance can predict clinical outcomes such as heart failure, ascites (development of fluid in the abdomen which can result from heart failure or liver failure), and need for heart transplant.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Hospital of the University of Pennsylvania
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- s/p Fontan operation
- cardiac catheterization or cardiac MRI within 1 year of enrollment
Exclusion Criteria:
- pregnant or breastfeeding
- unable to comprehend and/or give informed consent
- sensitivity to human serum albumin, or its preparations
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Fontan patient
Cholate assay will be administered once to Fontan patients and blood specimens will be collected to analyze cholate clearance.
|
Labeled oral and IV cholate will be administered once to the Fontan cohort and blood specimens will be collected at baseline and timepoints thereafter.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Hepatic cholate clearance
Tidsramme: Through study completion, an average of 1 year
|
D4-cholate and 13C-cholate clearance
|
Through study completion, an average of 1 year
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of adverse clinical outcomes
Tidsramme: 5 years after cholate assay
|
combined outcome of occurrence of any of the following: heart failure admission, clinically significant ascites, protein losing enteropathy, referral for cardiac transplantation, death
|
5 years after cholate assay
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Yuli Kim, MD, University of Pennsylvania
- Ledende efterforsker: Maarouf Hoteit, MD, Hospital of the University of Pennslyvania
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 829578
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Fontan-procedure
-
Children's Hospital Medical Center, CincinnatiAfsluttet
-
Children's Hospital Medical Center, CincinnatiAmerican Heart AssociationAfsluttet
-
Mayo ClinicNational Heart, Lung, and Blood Institute (NHLBI)RekrutteringFontan PalliationForenede Stater
-
University of MichiganAfsluttetFontan-procedureForenede Stater
-
St. Boniface HospitalIkke rekrutterer endnu
-
Stanford UniversityAfsluttetFontan FysiologiForenede Stater
-
Milton S. Hershey Medical CenterChildren's Miracle NetworkAfsluttetFontan CirkulationForenede Stater
-
University of MichiganAfsluttet
-
University of MichiganAfsluttetFontan PalliationForenede Stater
-
University Hospital Inselspital, BerneMach Gaensslen FoundationAfsluttet
Kliniske forsøg med Cholate assay
-
Northwestern UniversityUniversity of Colorado, DenverAfsluttetKardiovaskulær sygdom | Lever sygdom
-
National Institute of Diabetes and Digestive and...Afsluttet
-
University of Colorado, DenverAfsluttetLever sygdomForenede Stater
-
Tianjin Medical University General HospitalAfsluttetPåvisning Autoantistof af Myasthenia GravisKina
-
Oxford ImmunotecAfsluttet
-
Beckman Coulter, Inc.Afsluttet
-
Abbott Diagnostics DivisionAfsluttet
-
Fred Hutchinson Cancer CenterFox Chase Cancer Center; City of Hope Medical Center; Stanford University; Cedars-Sinai... og andre samarbejdspartnereAfsluttetEpitelial ovariecancerForenede Stater
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Beth Israel Deaconess Medical Center; Boston...RekrutteringLungekræft | EGFR-genmutationForenede Stater
-
Guangdong Women and Children HospitalRekruttering